2seventy bio (TSVT) to Release Quarterly Earnings on Tuesday

2seventy bio (NASDAQ:TSVT) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

2seventy bio (NASDAQ:TSVT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. 2seventy bio had a negative net margin of 354.16% and a negative return on equity of 66.01%. The firm had revenue of $8.97 million for the quarter, compared to the consensus estimate of $11.43 million. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Stock Performance

NASDAQ:TSVT traded up $0.21 during midday trading on Tuesday, reaching $4.72. 168,631 shares of the stock traded hands, compared to its average volume of 771,168. The business has a 50-day moving average of $4.74 and a two-hundred day moving average of $4.50. 2seventy bio has a 12-month low of $1.53 and a 12-month high of $6.40. The stock has a market capitalization of $243.08 million, a PE ratio of -1.47 and a beta of 1.78.

Insider Buying and Selling at 2seventy bio

In other news, insider Jessica Snow sold 7,816 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $4.32, for a total value of $33,765.12. Following the completion of the transaction, the insider now directly owns 156,330 shares in the company, valued at $675,345.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, Morgan Stanley decreased their price objective on 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.